Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024
Cardiovascular Restructuring Under Way At J&J
Public Company Edition: BioAge will fund a Phase II trial of its muscle atrophy prevention drug in combination with an obesity drug with its initial public offering proceeds. Also, Ascendis and Wave raised $281.3m and $200m, respectively, after positive clinical trial readouts.
